Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06410924Phase 2Completed

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Role: lead

NCT04154072Phase 2Completed

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Role: lead

NCT04812262Phase 1Completed

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Role: lead

NCT04159766Phase 2Completed

A Study With NLY01 in Subjects With Type 2 Diabetes

Role: lead

NCT03672604Phase 1Completed

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

Role: lead

All 5 trials loaded